NDA 021794 · Almirall
Aczone
Dapsone · Topical · Sulfone
Last checked: Nov 20, 2026Latest source record: May 18, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Jul 7, 2005
Approved uses
2
Original approval plus efficacy supplements
Registered trials
78
24 Phase 3, 2 recruiting
FAERS reports
10,863
8,218 serious, 935 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 30, 2018.
Dapsone gel, 5%, is indicated for the topical treatment of acne vulgaris. Dapsone gel is indicated for the topical treatment of acne vulgaris ( 1 ).
Mechanism: The mechanism of action of dapsone gel in treating acne vulgaris is not known.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 14, 2008 Supplement 5 · Efficacy LabelLetter
- Jul 7, 2005 Original approval · Type 3 - New Dosage Form LetterReviewLabel
1 products under this application
- ACZONE · DAPSONE 5% · GEL, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Dapsone" as an intervention, any sponsor and status, largest first.
- Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African ChildrenPivotal-lookingCompleted
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
NCT00393679 · 4,112 participants · Start Jul 2007 · Primary completion Dec 2009
Drug: amodiaquine-artesunate (ASAQ); dihydroartemisinin-piperaquine (DHAPQ) and 2 more · For: Fever; Malaria
Sites: Bobo-Dioulasso, Burkina Faso; Lambaréné, Gabon; Manhiça, Mozambique · 8 sites in all
- Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity SyndromePivotal-lookingStatus unknown
Shandong Provincial Institute of Dermatology and VenereologyAcademic, hospital or other
NCT02550080 · 3,130 participants (planned) · Start Jul 2015 · Primary completion Dec 2018
Drug: Dapsone · For: Allergic Cutaneous Vasculitis; Urticaria; Psoriasis and 5 more
Sites: Jinan, China
- Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19Pivotal-lookingStatus unknown
McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
NCT04935476 · 3,000 participants (planned) · Start Nov 22, 2021 · Primary completion Mar 31, 2022
Drug: Dapsone 85 mg PO BID; Placebo 85 mg PO BID · For: COVID-19
Sites: Phoenix, Arizona; High Point, North Carolina; Philadelphia, Pennsylvania · 7 sites in all
- Kilimanjaro IPTi Drug Options TrialPivotal-lookingCompleted
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT00158574 · 2,419 participants · Start Jan 2005 · Primary completion Apr 2008
Drug: sulphadoxine-pyrimethamine; mefloquine and 5 more · For: Malaria
Sites: Tanga, Tanzania
- Trial of Dapsone 5.0% Gel in the Treatment of Acne VulgarisPivotal-lookingCompleted
Seegpharm S.A.Industry
NCT02865005 · 2,361 participants · Start Feb 2016 · Primary completion Nov 2016
Drug: Dapsone 5.0% Gel (SEEGPharm); Dapsone 5.0% Gel (Allergan) · For: Acne Vulgaris
Sites: Encino, California; Fullerton, California; La Mesa, California · 36 sites in all
- Safety and Efficacy Study of Dapsone Gel in Patients With Acne VulgarisPivotal-lookingCompleted
Almirall, S.A.Industry
NCT01974323 · 2,238 participants · Start Nov 2013 · Primary completion Oct 2014
Drug: Dapsone Gel; Dapsone Gel Vehicle · For: Acne Vulgaris
Sites: Beverly Hills, California; Aventura, Florida; Windsor, Canada
- A Safety and Efficacy Study of Dapsone Gel in Patients With Acne VulgarisPivotal-lookingCompleted
Almirall, S.A.Industry
NCT01974141 · 2,102 participants · Start Nov 2013 · Primary completion Oct 2014
Drug: Dapsone Gel; Dapsone Gel Vehicle · For: Acne Vulgaris
Sites: Encino, California; North Bay, Canada
- Intermittent Preventive Treatment With Antimalarials in Kenyan InfantsPivotal-lookingCompleted
Centers for Disease Control and PreventionFederal agency
NCT00111163 · 1,516 participants · Start Mar 2004 · Primary completion Mar 2006
Drug: sulfadoxine-pyrimethamine with artesunate; amodiaquine with artesunate and 1 more · For: Malaria; Anemia
Sites: Asembo (Rarieda Division), Kenya
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,306
- drug ineffective1,166
- methaemoglobinaemia498
- nausea492
- fatigue487
- pyrexia474
- diarrhoea426
- rash405
- drug reaction with eosinophilia and systemic symptoms399
- dyspnoea392
- pneumonia385
- pain376
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 143 |
| 2005 | 145 |
| 2006 | 165 |
| 2007 | 104 |
| 2008 | 193 |
| 2009 | 232 |
| 2010 | 212 |
| 2011 | 232 |
| 2012 | 274 |
| 2013 | 173 |
| 2014 | 311 |
| 2015 | 441 |
| 2016 | 566 |
| 2017 | 647 |
| 2018 | 732 |
| 2019 | 733 |
| 2020 | 927 |
| 2021 | 709 |
| 2022 | 807 |
| 2023 | 687 |
| 2024 | 872 |
| 2025 | 890 |
| 2026 | 665 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Aczone (Dapsone)
2024 spending
$78K
Beneficiaries
37
90 claims
Per beneficiary
$2,104
$12.79 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $136,577 |
| 2021 | $200,150 |
| 2022 | $154,571 |
| 2023 | $89,314 |
| 2024 | $77,862 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K, Williams J, Qi YP, et al. · Cochrane Database Syst Rev 2022 · English Abstract, Meta-Analysis
- Treatment of urticarial vasculitis: A systematic review.
Kolkhir P, Grakhova M, Bonnekoh H, et al. · J Allergy Clin Immunol 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis.
Chu AWL, Oykhman P, Chu X, et al. · J Allergy Clin Immunol 2025 · Comparative Study, Network Meta-Analysis
- Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Prosty C, Katergi K, Sorin M, et al. · Clin Microbiol Infect 2024 · Systematic Review, Comparative Study
- Comparative efficacy and safety of treatment regimens for Pneumocystis jirovecii pneumonia in people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Hatzl S, Posch F, Scholz L, et al. · Clin Microbiol Infect 2025 · Systematic Review, Comparative Study
- [Pemphigus: a review].
Joly P, Sin C · Ann Dermatol Venereol 2011 · Systematic Review
Sponsor: Almirall
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.